US FDA told to prioritise OTC drug review

27 March 2014 - Deborah Wilkes

Archived

The US OTC drug review is in a "slow death spiral" because the Center for Drug Evaluation and Research (CDER) has decided "OTC drugs are unimportant and trivial", according to Peter Barton Hutt, former chief counsel at the US Food and Drug Administration (FDA).

Click tags below for more information on topics:

FDA

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: